title: The effect of topical bevacizumab on corneal neovascularization.
abstract: OBJECTIVE
  To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.
  
  
  METHODS
  Prospective, nonrandomized, masked observational case series.
  
  
  METHODS
  Ten eyes of 7 patients with corneal NV.
  
  
  METHODS
  Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.
  
  
  METHODS
  Corneal NV and changes in ophthalmic evaluations.
  
  
  RESULTS
  Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.
  
  
  CONCLUSIONS
  Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
authors.affiliation: Corneal Dystrophy Research Institute, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
authors.forename: Sang Woo
authors.initials: SW
authors.lastname: Kim
authors.forename: Byung Jin
authors.initials: BJ
authors.lastname: Ha
authors.forename: Eung Kweon
authors.initials: EK
authors.lastname: Kim
authors.forename: Hungwon
authors.initials: H
authors.lastname: Tchah
authors.forename: Tae-im
authors.initials: TI
authors.lastname: Kim
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D019573:Epithelium, Corneal / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab